1. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
- Author
-
Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, and Rouru J
- Subjects
- Adolescent, Adult, Aged, Anti-Anxiety Agents administration & dosage, Camphanes administration & dosage, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Anti-Anxiety Agents therapeutic use, Anxiety Disorders drug therapy, Camphanes therapeutic use
- Abstract
Deramciclane, a camphor derivative, is a novel anxiolytic agent with a unique mechanism of action. It acts as a potent and specific antagonist at serotonin 5-HT2A/2C receptors, and exhibits anxiolytic efficacy in animal models. The aim of this double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of a range of doses of deramciclane in patients with generalized anxiety disorder (GAD). Adult patients with a diagnosis of GAD (DSM-IV) and a Hamilton Anxiety Rating Scale (HAM-A) total score >or=18; a score >or=2 for the HAM-A items 'Anxious Mood' and 'Tension'; a score >or=4 on the Clinical Global Impression of Severity of Illness (CGI-S) Scale; and a score
- Published
- 2005
- Full Text
- View/download PDF